UK markets open in 7 hours 53 minutes
  • NIKKEI 225

    27,820.40
    +42.50 (+0.15%)
     
  • HANG SENG

    19,518.29
    +842.94 (+4.51%)
     
  • CRUDE OIL

    77.40
    +0.47 (+0.61%)
     
  • GOLD FUTURES

    1,781.20
    -0.10 (-0.01%)
     
  • DOW

    33,947.10
    -482.78 (-1.40%)
     
  • BTC-GBP

    13,929.56
    -161.15 (-1.14%)
     
  • CMC Crypto 200

    401.03
    -10.19 (-2.48%)
     
  • ^IXIC

    11,239.94
    -221.56 (-1.93%)
     
  • ^FTAS

    4,143.21
    +4.40 (+0.11%)
     

Aquis Stock Exchange: Update to Application for Admission Announcement

Aquis Stock Exchange
Aquis Stock Exchange: Update to Application for Admission Announcement
27-Oct-2022 / 07:00 GMT/BST


ANNOUNCEMENT OF APPLICATION FOR ADMISSION TO THE AQSE GROWTH MARKET

 

APPLICANT NAME:


TECC Capital Plc (“Company”) (to be renamed EDX Medical Group Plc(“EDX”))

APPLICANT REGISTERED OFFICE, PRINCIPAL PLACE OF BUSINESS (IF DIFFERENT) AND TELEPHONE NUMBER:

Principle business address:
Unit 210-211 Cambridge Science Park, Milton Road, Cambridge, United Kingdom, CB4 0WA

Registered office:
201 Temple Chambers, 3-7 Temple Avenue, London, EC4Y 0DT

DIRECTORS AND PROPOSED DIRECTORS (IF APPLICABLE):


Existing (resigning conditional on re-admission)
John Edward Taylor (Executive director)
Alexander (Sandy) Barblett (Non-executive Chairman)
Donald Stewart (Non-executive director)

Proposed
Professor Sir Christopher Evans (Chief Scientific Officer)
Dr Mike Hudson (Chief Executive Officer)
Jason Holt (Non-executive Chairman)
Trevor Jones (Non-executive director)

APPLICANT SECTOR:

Pharmaceuticals & Biotechnology

DESCRIPTION OF THE APPLICANT AND ITS ACTIVITIES:


EDX operates a molecular biology and diagnostics laboratory in Cambridge, UK, from which it performs research & development (R&D), provides Polymerase Chain Reaction (PCR) testing and genomic sequencing services, undertakes quality assurance and has established expertise in the design, development, validation and sourcing of Lateral Flow Tests (LFTs) on a commercial scale. Key tests performed in this laboratory have been audited by the United Kingdom Accreditation Service (UKAS) and accredited to ISO 15189. From this foundation, EDX intends to further invent, in-licence, develop, protect and validate proprietary products and technologies primarily focussed beyond Covid, providing globally-relevant healthcare diagnostic solutions that are digitally robust, secure, accessible and trusted by both consumers and healthcare professionals. The Proposed Directors believe that EDX will deliver cost-effective and reliable solutions to businesses, governments, health professionals and individuals in the UK, Europe and selected international markets determined by its business partnerships as first priority.

Business model
EDX is an ambitious pioneer in digital diagnostics intending to grow by organic innovations, acquisition/licensing and strategic collaborations in the public and private sector. EDX is investing to develop and secure a significant early ‘bridgehead’ in respect of its market position in the UK and Europe based on three pillars:

• diagnostics services for clinical healthcare providers;
• companion diagnostics to support pharma development and clinical trials; and
• public sector disease surveillance programmes.

EDX is building capabilities to provide future business partners, individuals and their professional advisors with access to a suite of robust and reliable testing solutions for predicting disease risk, confirming diagnosis and monitoring management, providing real-time, secure digital data / reporting.

Securing access to potential class-leading screening products and key biotechnologies via strategic partnerships is a key objective for EDX.

NAME OF AQSE CORPORATE ADVISER:


Peterhouse Capital Limited

NUMBER, CLASS AND PAR VALUE OF SECURITIES TO BE ADMITTED:


250,833,333 Ordinary Shares of £0.01 each

SECURITIES IN PUBLIC HANDS AS A PERCENTAGE OF THE TOTAL NUMBER OF SECURITIES IN ISSUE (excluding securities held in treasury):


Circa 28%

SHAREHOLDERS HOLDING MORE THAN FIVE PER CENT OF THE APPLICANT’S SHARE CAPITAL OR VOTING RIGHTS PRE- AND POST-ADMISSION:

 

Name

Pre

Post

Chris Akers

11.1%

1.33%

Monecor (London) Limited

15.8%

1.89%

Christopher Evans

-

49.44%

Mike Hudson

-

7.97%

Countrywide Developments

-

7.97%

West Coast Capital Holdings

-

6.38%


TIMETABLE FOR ANY OFFER OF TRANSFERABLE SECURITIES TO THE PUBLIC:

N/A

THE EXPECTED ADMISSION DATE:

On or around 14 November 2022

WEBSITE ADDRESS WHERE INVESTOR INFORMATION WILL BE AVAILABLE FOR INSPECTION:

https://www.edxmedical.co.uk/


In respect of a fast-track applicant, the following information should also be included:

NAME OF MARKET ON WHICH THE APPLICANT’S SECURITIES ARE CURRENTLY TRADED:

 

ARRANGEMENTS FOR THE SETTLEMENT OF TRANSACTIONS IN THE APPLICANT’S SECURITIES:

 

DETAILS OF ANY LOCK-IN ARRANGEMENTS:

 

DETAILS OF THE LEGAL OR REGULATORY REQUIREMENTS IN THE APPLICANT’S HOME COUNTRY REGARDING THE CONDUCT OF TAKEOVERS AND THE ACQUISITION OF SIGNIFICANT VOTING RIGHTS TO WHICH THE APPLICANT IS SUBJECT:

 


In respect of an update to a prior application announcement, the date of the original announcement should also be disclosed as follows:
 

UPDATE TO A PRIOR APPLICATION ANNOUNCEMENT RELEASED ON:

29 September 2022


Dissemination of a CORPORATE NEWS, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.

End of Announcement - EQS News Service

show this
show this